PCA
SUPN icon

Providence Capital Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Providence Capital Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-130
Closed -$4K – 323
2018
Q4 		$4K Hold
130
– – ﹤0.01% 227
2018
Q3 		$7K Hold
130
– – ﹤0.01% 216
2018
Q2 		$8K Hold
130
– – 0.01% 199
2018
Q1 		$6K Hold
130
– – ﹤0.01% 214
2017
Q4 		$5K Buy
+130
New +$5.14K ﹤0.01% 265

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Providence Capital Advisors's SUPN Position: Q1 2019 in Review

Providence Capital Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 130 shares — an estimated $4K sold.

Providence Capital Advisors first reported a position in SUPN in Q4 2017 and held it in 5 quarters. The position peaked at $8K in Q2 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • Providence Capital Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Providence Capital Advisors sold 130 Supernus Pharmaceuticals shares in Q1 2019, an estimated $4K.
  • Providence Capital Advisors first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • Providence Capital Advisors's Supernus Pharmaceuticals position peaked at $8K in Q2 2018.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Providence Capital Advisors's 13F filing for Q1 2019, filed 8 May 2019.